File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Update on clarithromycin resistance in Helicobacterpylori in Hong Kong and its effect on clarithromycin-based triple therapy

TitleUpdate on clarithromycin resistance in Helicobacterpylori in Hong Kong and its effect on clarithromycin-based triple therapy
Authors
Issue Date2005
PublisherBlackwell Publishing Asia.
Citation
Asian Pacific Digestive Week, Seoul, Korea, 25-28 September 2005. In Journal of Gastroenterology and Hepatology, 2005, v. 20 n. S2, p. A160 Abstract no. MP034 How to Cite?
AbstractAim To update the antibiotic susceptibility of Helicobacter pylori andevaluate the efficacy of a clarithromycin-based triple therapy in rela-tion to metronidazole and/or clarithromycin resistance in Hong Kong. Methods Consecutive patients referred for upper endoscopy due todyspeptic symptoms were recruited. Gastric biopsies were obtainedfor the CLO test, histology and culture. Antibiotic susceptibility wasassessed by the E-test. Patients with H. pylori infection receivedrabeprazole 20mg, clarithromycin 500 mg, and amoxicillin 1000mg,all twice daily for 7 days.13C-urea breath test was performed threemonths after treatment.Results A total of 125 patients were recruited. Culture of H. pyloriwas successful in 102 (81.6%) patients. The prevalence of antibioticresistance to metronidazole, clarithromycin and amoxicillin were39.2%, 4.9% and 0%, respectively. A total of 86 patients received oneweek triple therapy, and 81 patients attended the follow-up test. Erad-ication rates by per protocol and intention-to-treat analysis were92.6% and 87.2%, respectively. The regimen achieved significantlyhigher eradication rate for patients with clarithromycin sensitivestrains than that for those with clarithromycin resistant strains (94.8%vs. 50%, P = 0.027), whereas there was no significant difference inthe eradication rate between metronidazole-sensitive and resistantstrains.Conclusion The updated prevalence of resistance to metronida-zole, clarithromycin and amoxicillin in Hong Kong is 39.2%, 4.9%and 0%, respectively. Clarithromycin resistance influences the clini-cal efficacy of clarithromycin-based triple therapy. However due tothe low prevalence of clarithromycin resistance, clarithromycin-basedtherapy is still the first choice for clinical use.(This study is supported by a research grant from the Hong KongDigestive Foundation, Hong Kong.)
Persistent Identifierhttp://hdl.handle.net/10722/102636
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190

 

DC FieldValueLanguage
dc.contributor.authorGu, Qen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorWang, Jen_HK
dc.contributor.authorChan, OOen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorWong, KWen_HK
dc.contributor.authorCheung, KLen_HK
dc.contributor.authorKung, H-
dc.contributor.authorWong, BCY-
dc.date.accessioned2010-09-25T20:38:39Z-
dc.date.available2010-09-25T20:38:39Z-
dc.date.issued2005en_HK
dc.identifier.citationAsian Pacific Digestive Week, Seoul, Korea, 25-28 September 2005. In Journal of Gastroenterology and Hepatology, 2005, v. 20 n. S2, p. A160 Abstract no. MP034en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102636-
dc.description.abstractAim To update the antibiotic susceptibility of Helicobacter pylori andevaluate the efficacy of a clarithromycin-based triple therapy in rela-tion to metronidazole and/or clarithromycin resistance in Hong Kong. Methods Consecutive patients referred for upper endoscopy due todyspeptic symptoms were recruited. Gastric biopsies were obtainedfor the CLO test, histology and culture. Antibiotic susceptibility wasassessed by the E-test. Patients with H. pylori infection receivedrabeprazole 20mg, clarithromycin 500 mg, and amoxicillin 1000mg,all twice daily for 7 days.13C-urea breath test was performed threemonths after treatment.Results A total of 125 patients were recruited. Culture of H. pyloriwas successful in 102 (81.6%) patients. The prevalence of antibioticresistance to metronidazole, clarithromycin and amoxicillin were39.2%, 4.9% and 0%, respectively. A total of 86 patients received oneweek triple therapy, and 81 patients attended the follow-up test. Erad-ication rates by per protocol and intention-to-treat analysis were92.6% and 87.2%, respectively. The regimen achieved significantlyhigher eradication rate for patients with clarithromycin sensitivestrains than that for those with clarithromycin resistant strains (94.8%vs. 50%, P = 0.027), whereas there was no significant difference inthe eradication rate between metronidazole-sensitive and resistantstrains.Conclusion The updated prevalence of resistance to metronida-zole, clarithromycin and amoxicillin in Hong Kong is 39.2%, 4.9%and 0%, respectively. Clarithromycin resistance influences the clini-cal efficacy of clarithromycin-based triple therapy. However due tothe low prevalence of clarithromycin resistance, clarithromycin-basedtherapy is still the first choice for clinical use.(This study is supported by a research grant from the Hong KongDigestive Foundation, Hong Kong.)-
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia.en_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.titleUpdate on clarithromycin resistance in Helicobacterpylori in Hong Kong and its effect on clarithromycin-based triple therapyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=20 &issue=Suppl.&spage=A160&epage=&date=2005&atitle=Update+on+clarithromycin+resistance+in+Helicobacter+pylori+in+Hong+Kong+and+its+effect+on+clarithromycin-based+triple+therapy.en_HK
dc.identifier.emailGu, Q: qingappl@hotmail.comen_HK
dc.identifier.emailXia, HHX: xiaharry@hotmail.comen_HK
dc.identifier.emailWang, J: jidewang@gmail.comen_HK
dc.identifier.emailChan, OO: aoochan@hku.hken_HK
dc.identifier.emailLai, KC: kclai@HKUCC.hku.hken_HK
dc.identifier.emailFung, FMY: fionafung20@hotmail.comen_HK
dc.identifier.emailKung, H: hkung@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityWang, J=rp00491en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1746.2005.04098.x-
dc.identifier.hkuros112802en_HK
dc.identifier.volume20en_HK
dc.identifier.issueSuppl.en_HK
dc.identifier.spage160en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats